• Profile
Close

Time–kill analysis of ceftolozane/tazobactam efficacy against mucoid Pseudomonas aeruginosa strains from cystic fibrosis patients

Infectious Diseases and Therapy Oct 26, 2017

Rac H, et al. - In this study, the susceptibility of mucoid Pseudomonas aeruginosa (MP) strains to ceftolozane/tazobactam was examined, as well as the efficacy of ceftolozane/tazobactam against MP strains compared with those for standard-of-care antipseudomonal antibiotics. Findings demonstrated that at both the 1.5-g dose and the 3-g dose, ceftolozane/tazobactam activity against MP strains derived from cystic fibrosis (CF) patients was comparable to that of standard-of-care agents.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay